RenaissanceRe sells insurance to insurance companies. When a primary insurer like a Florida homeowners carrier writes thousands of policies, it can't afford to keep the whole hurricane risk itself. It pays RenRe a premium to take the big, rare losses off its books. RenRe collects that premium up front, invests it, and pays out when a major catastrophe hits. Founded in Bermuda in 1993 after Hurricane Andrew, it is one of the world's leading property-catastrophe reinsurers.
| Property | Catastrophe reinsurance for hurricanes, earthquakes, wildfires and floods (the original RenRe franchise), plus other property lines. Highly profitable in quiet years, with big losses in heavy-catastrophe years such as 2017 and 2022. Priced with its own in-house catastrophe models. |
| Casualty & Specialty | Liability, professional lines, credit, cyber, marine and similar risks. Now roughly 60% of premiums, a share that grew with the November 2023 Validus acquisition from AIG. Lower-margin and steadier, but long-tail: claims show up years later, so reserve adequacy is the risk. |
| Capital Partners | Manages about $7B of outside investors' money through joint ventures and funds (DaVinci, Medici cat-bond fund, Fontana). RenRe earns about $330M a year in management and performance fees, and outside capital absorbs part of the catastrophe losses. |
| Investment float | About a $36B bond portfolio funded by premiums held before claims are paid, plus equity. At a ~5.3% yield it generates about $1.7B a year of net investment income, the biggest change versus the zero-rate decade. |
Why the P/E is distorted (and it isn't investment gains). TTM net income to common is $2.60bn, but TTM operating income is nearly the same at $2.47bn. Mark-to-market gains in H2-25 (+$1.2bn in FY25) were offset by −$300m in H1-26. The real distortions are underwriting. H2-25 and H1-26 were cat-light (1H26 global insured nat-cat losses were $44bn vs $95bn in 1H25, and the 2026 Atlantic season has been quiet so far). FY25 also booked $1.09bn of favourable prior-year development (11 pts). Strip those out and normalized EPS is about $36, so the true multiple is 9.5x, not 6x.
Normalized ROE: 13.3%. RNR's 10-year combined ratio (2016–25, including 2017's 137.9% HIM year and 2022's Ian year) averages 94.1%. We use 94% and rebuild FY25 operating income at that combined ratio, at a 5.3% portfolio yield (YTM at 30-Jun, duration 3.0) and at 2027E premiums ~5% lower. The historical 10-year ROE of 9.8% is not the right anchor because it was earned at 1–3% bond yields. Today net investment income alone is worth ~13% of common equity pre-tax. That is the structural change: the float now earns real money even if underwriting only breaks even. At the 2023–25 average combined ratio (83%) ROE would be 21%, so we are deliberately not capitalizing peak-cycle underwriting.
The cycle is turning against them. Property-cat rates fell ~12% at 1/1/26 (up to −20% for loss-free US risk) and ~16% at mid-year (Florida up to −25%). Fitch and JPM see further softening at 1/1/27 if the wind season stays quiet; Hannover Re expects the declines to slow, not reverse. Our base takes ROE 1.5pt below normal in 2028–29 and lets ILS and alternative capital erode 1pt of the spread permanently in the terminal value. Casualty is the slow-burn risk: C&S posted $58m of adverse development in Q2-26 (social inflation, the inherited Validus book). We deduct a $7/share expected reserve charge in the base and $20 in the bear.
The math: at a 9.6% cost of equity (Rf 5.2% + 1.0 × 4.4%; we use beta 1.0 rather than the ~0.5 regression beta to price the cat tail) and 3.5% growth, the excess-return model gives $387 (1.43x Q3E BV of $272). The price implies a normalized ROE of 12.2% (≈ a 95.5% normalized combined ratio, a shade worse than the 10-year average) or a 10.4% cost of equity. Book value has compounded at 9.6% a year for 10 years through two catastrophic years. Buybacks (~$1.6bn in 2025, −12.8% share count; $350m in Q2-26 at $301) are accretive below ~1.4x.
Call: Hold / accumulate on weakness below ~$320 (≈1.18x Q3E BV, about 17% under base). Fair value is ~$387; trim above ~$420. The stock is at its 52-week high into a likely strong Q3 print (late October; we estimate Q3E BV ~$272), and the 1/1/27 renewal commentary is the swing factor. Best options expression: sell cash-secured puts or a bull put spread with the short strike ~$310–315 (≈1.15x Q3E BV), 45–75 DTE, opened after the Q3 print once event IV has collapsed. A major landfall would gap the stock 10–15%, so size for that.
| HIGH | Catastrophe tail: long hurricane, earthquake and wildfire risk (Florida, Gulf, California, Japan). A 1-in-100 event costs roughly 15–25% of BV in one quarter (2017: −8% BV/share; 2022: −21%). |
| HIGH | Pricing cycle: short reinsurance rate adequacy as capital floods in (record ILS issuance, cat bonds). Property-cat rates −12% / −16% in 2026, with more expected at 1/1/27. |
| MED | Casualty reserves: short US social inflation. The C&S book is ~60% of premiums, Q2-26 had $58m adverse, and the Validus casualty vintages are 2019–22. |
| MED | Interest rates: long yields. NII is ~$1.7bn a year (5.3% YTM, duration 3). A 130bp lower yield removes ~3pt of ROE. A 10Y spike causes MTM book losses (Q3E −$5/share) but raises future income. |
| LOW | Capital and leverage: debt $2.3bn and preferred $0.75bn against $11.8bn equity. Third-party capital ($7.3bn NCI) absorbs part of the cat losses and pays fees (~$330m a year). |
| Normalized ROE ↓ / Cost of equity → | 8.5% | 9.0% | 9.6% | 10.0% | 11.0% |
| 10.0% | $296.7 | $270.2 | $244.1 | $229.4 | $199.4 |
| 11.5% | $376.1 | $342.3 | $309.2 | $290.4 | $252.3 |
| 13.0% | $455.5 | $414.5 | $374.2 | $351.5 | $305.2 |
| 13.3% (base) | $471.3 | $428.9 | $387.2 | $363.7 | $315.8 |
| 16.0% | $614.2 | $558.8 | $504.3 | $473.6 | $411.1 |
| 17.5% | $693.6 | $631.0 | $569.4 | $534.6 | $464.0 |
| Year | NI to common $m | Common equity $m | Net ROE | Operating ROE | Combined ratio | BVPS |
| 2014 | 510 | 3,466 | 14.6% | 13.7% | 50.2% | $90.15 |
| 2015 | 409 | 4,332 | 10.5% | 11.4% | 64.7% | $99.13 |
| 2016 | 481 | 4,467 | 10.9% | 7.8% | 72.5% | $108.45 |
| 2017 ★ | -245 | 3,741 | -6.0% | -7.7% | 137.9% | $99.72 |
| 2018 | 197 | 4,395 | 4.8% | 8.4% | 87.6% | $104.13 |
| 2019 | 712 | 5,321 | 14.7% | 8.0% | 92.3% | $120.53 |
| 2020 | 732 | 7,035 | 11.8% | 0.2% | 101.9% | $138.46 |
| 2021 | -73 | 5,874 | -1.1% | 1.3% | 102.1% | $132.17 |
| 2022 ★ | -1,097 | 4,575 | -21.0% | 6.4% | 97.7% | $104.65 |
| 2023 | 2,526 | 8,705 | 38.0% | 29.3% | 77.9% | $165.20 |
| 2024 | 1,835 | 9,824 | 19.8% | 23.5% | 83.9% | $195.77 |
| 2025 | 2,647 | 10,859 | 25.6% | 18.2% | 87.2% | $247.00 |
| 10-yr avg 2016–25 | 9.8% | 9.5% | 94.1% | CAGR 9.6% | ||
| 12-yr avg 2014–25 | 88.0% | |||||
| TTM Jun-26 | 2,598 | 11,070 | ~24% | ~23% | light-cat | $264.77 |
| Year | Opening BV (after reserve charge) | ROE | EPS | CoE | Excess return | PV |
| 2027 | $264.57 | 14.3% | $37.83 | 9.6% | $12.43 | $11.34 |
| 2028 | $273.83 | 11.8% | $32.31 | 9.6% | $6.02 | $5.01 |
| 2029 | $283.41 | 11.8% | $33.44 | 9.6% | $6.23 | $4.74 |
| 2030 | $293.33 | 12.8% | $37.55 | 9.6% | $9.39 | $6.50 |
| 2031 | $303.60 | 13.3% | $40.38 | 9.6% | $11.23 | $7.10 |
| Terminal | Stable ROE 12.3% (spread eroded 1pt), g 3.5% → justified P/BV 1.44x | $87.9 | ||||
For an insurer, debt and float are raw material, not financing. Claims reserves are the "debt" that funds the investment portfolio, so operating and financing cash flows can't be separated and an EV or FCFF framework double-counts or misprices the float. Damodaran's method for financials values equity directly: book value plus the present value of returns above the cost of equity. For a cat reinsurer, the only honest earnings input is a through-cycle ROE, because one quarter can erase a year.
| Risk-free (10Y UST, Sept-2026 spike) | 5.20% |
| Mature ERP | 4.40% |
| Beta: regression ~0.5 (cat risk is uncorrelated with the market); we use 1.0 to price the fat tail and the regime risk | 1.00 |
| Cost of equity | 9.60% |
| Stable growth in BV/share (insured-value inflation plus modest real growth) | 3.5% |
| BV/share 30-Jun-26 (12/31/25: $247.00) · TBV/share (TBV + accumulated dividends $278.16 − $30.48) | $264.77 · $247.68 |
| Q3-26E roll-forward: op EPS +$13.5 (light cat), bond MTM −$5, dividend −$0.40, buyback above book −$1.3 | BV ≈ $271.57 |
| Common equity / preferred / debt / redeemable NCI (30-Jun-26) | $11.07bn / $0.75bn / $2.33bn / $7.34bn |
| Total investments · YTM · duration | $36.2bn · 5.3% · 3.0 yrs |
| FY25 NPE / NII / fee income / PYD | $9.90bn / $1.70bn / $0.33bn / −$1.09bn |
| H1-26 op ROE (annualized) / combined ratio Q2 (Property 27.1%, C&S 103.3%) | 20.9% / 72.8% |
| Shares outstanding (RH) · market cap | 41.55m · $14.2bn |
| P/E: TTM net / TTM operating / normalized | 5.9x / ~5.9x / 9.5x |
| Market-implied normalized ROE / CoE | 12.2% / 10.4% |